816 related articles for article (PubMed ID: 15967846)
1. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
[TBL] [Abstract][Full Text] [Related]
2. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
[TBL] [Abstract][Full Text] [Related]
3. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
[TBL] [Abstract][Full Text] [Related]
5. Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction.
Foster RE; Johnson DB; Barilla F; Blackwell GG; Orr R; Roney M; Stanley AW; Pohost GM; Dell'Italia LJ
Am Heart J; 1998 Aug; 136(2):269-75. PubMed ID: 9704689
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
7. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Aguilar D; Solomon SD; Køber L; Rouleau JL; Skali H; McMurray JJ; Francis GS; Henis M; O'Connor CM; Diaz R; Belenkov YN; Varshavsky S; Leimberger JD; Velazquez EJ; Califf RM; Pfeffer MA
Circulation; 2004 Sep; 110(12):1572-8. PubMed ID: 15364810
[TBL] [Abstract][Full Text] [Related]
8. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Reed SD; Radeva JI; Weinfurt KP; McMurray JJ; Pfeffer MA; Velazquez EJ; Allsbrook JS; Masselink LE; Sellers MA; Califf RM; Schulman KA;
Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
[TBL] [Abstract][Full Text] [Related]
9. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
Suşan M; Petrescu L; Riviş AI; Suşan RM; Burghină D; Dan R; Cozma D; Drăgulescu SI
Rom J Intern Med; 2005; 43(3-4):187-98. PubMed ID: 16812979
[TBL] [Abstract][Full Text] [Related]
10. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
[TBL] [Abstract][Full Text] [Related]
11. Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Reed SD; McMurray JJ; Velazquez EJ; Schulman KA; Califf RM; Kober L; Maggioni AP; Van de Werf F; White HD; Diaz R; Mareev V; Murin J;
Am Heart J; 2006 Sep; 152(3):500-8. PubMed ID: 16923421
[TBL] [Abstract][Full Text] [Related]
12. Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial.
Yerra L; Anavekar N; Skali H; Zelenkofske S; Velazquez E; McMurray J; Pfeffer M; Solomon SD
Heart Rhythm; 2006 Mar; 3(3):313-6. PubMed ID: 16500304
[TBL] [Abstract][Full Text] [Related]
13. Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
Shamshad F; Kenchaiah S; Finn PV; Soler-Soler J; McMurray JJ; Velazquez EJ; Maggioni AP; Califf RM; Swedberg K; Kober L; Belenkov Y; Varshavsky S; Pfeffer MA; Solomon SD;
Am Heart J; 2010 Jul; 160(1):145-51. PubMed ID: 20598985
[TBL] [Abstract][Full Text] [Related]
14. Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy.
Møller JE; Dahlström U; Gøtzsche O; Lahiri A; Skagen K; Andersen GS; Egstrup K;
Am Heart J; 2004 Mar; 147(3):494-501. PubMed ID: 14999200
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
Stephenson K; Skali H; McMurray JJ; Velazquez EJ; Aylward PG; Kober L; Van de Werf F; White HD; Pieper KS; Califf RM; Solomon SD; Pfeffer MA
Heart Rhythm; 2007 Mar; 4(3):308-13. PubMed ID: 17341394
[TBL] [Abstract][Full Text] [Related]
16. [Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study].
Rodríguez JA; Godoy I; Castro P; Quintana JC; Chávez E; Yovanovich J; Corbalán R; Chávez A
Rev Med Chil; 1997 Jun; 125(6):643-52. PubMed ID: 9515282
[TBL] [Abstract][Full Text] [Related]
17. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction.
Murcia AM; Hennekens CH; Lamas GA; Jiménez-Navarro M; Rouleau JL; Flaker GC; Goldman S; Skali H; Braunwald E; Pfeffer MA
Arch Intern Med; 2004 Nov; 164(20):2273-9. PubMed ID: 15534166
[TBL] [Abstract][Full Text] [Related]
18. Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function.
Amigoni M; Meris A; Thune JJ; Mangalat D; Skali H; Bourgoun M; Warnica JW; Barvik S; Arnold JM; Velazquez EJ; Van de Werf F; Ghali J; McMurray JJ; Køber L; Pfeffer MA; Solomon SD
Eur Heart J; 2007 Feb; 28(3):326-33. PubMed ID: 17251259
[TBL] [Abstract][Full Text] [Related]
19. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study.
Borghi C; Ambrosioni E;
Am Heart J; 2007 Mar; 153(3):445.e7-14. PubMed ID: 17307427
[TBL] [Abstract][Full Text] [Related]
20. Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Lam CS; McEntegart M; Claggett B; Liu J; Skali H; Lewis E; Køber L; Rouleau J; Velazquez E; Califf R; McMurray JJ; Pfeffer M; Solomon S
Eur J Heart Fail; 2015 Mar; 17(3):301-12. PubMed ID: 25655011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
